Figure 3. miR-103 decreases angiogenesis and tumour burden.

(a) GBM-NS-001 cells (2 × 10⁴) were orthotopically implanted into brains of nude mice. miRs were injected locally 7 days post tumour implantation (N=14 mice per group). P value from a log-rank (Mantel–Cox) test. (b) HCT116 colon carcinoma cells were implanted subcutaneously in nude mice. Mice were treated with 50 μg of either control miR or miR-103 mimic on days 6, 8 and 10 (black arrows). Mice received a single dose of 2 Gy radiation on day 8 (red arrows). Mean tumour volume measurements of N=8 mice per group are shown. Error bars represent s.e.m. *P<0.05 by Mann–Whitney U-test. (c) Angiogenesis was measured by staining tumour sections with anti-CD31. Quantification of CD31 area from at least three mice per group are shown. Bars show mean+s.e.m. *P<0.05, **P<0.01. (d) HCT cells were implanted as in b. (N=8 mice per group) Mice were treated with either a control mimic or mir-103 mimic in 7C1 nanoparticles (0.7 mg kg⁻¹ of miR, i.v.) on days 9,12 and 15 (black arrows) and were irradiated locally on days 10,12 and 16 (red arrows). Mean tumour volume measurements of N=8 mice per group are shown. Error bars represent s.e.m. *P<0.05 by Mann–Whitney U-test. (e) Angiogenesis was measured as in c. Bars show mean+s.e.m. *P<0.05 by two-tailed Student's t-test. (f,g) 4T1 mouse mammary carcinoma cells (1 × 10⁴) were implanted in the mammary fat pads of 6–8 week old female Balb/C mice (N=6 controls, 7 treated). Mice were randomized to receive either Control miR or miR-103 mimic formulated as miR-7C1 nanoparticles (0.7 mg kg⁻¹, i.v.) on days 12, 14, 16. Primary tumour volume measurements and gross metastatic foci per lung on day 20 are shown. Error bars depict s.e.m. *P<0.05 and **P<0.01 by Mann–Whitney U-test. (h) Angiogenesis was measured by staining the 4T1 tumour sections with anti-CD31. Bars show CD31 area normalized the tumour area as mean+s.e.m. from n=4 tumours per group. *P<0.05 by two-tailed Student's t-test.